News & Media

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/11/29

Medivir to present at the Erik Penser Bank Healthcare Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/11/21

Medivir recruits Pia Baumann as new Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/11/16

Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/11/09

Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/11/03 Regulatory

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2022

The measures to increase the pace of patient recruitment have yielded results. The Fostrox study is now progressing as expected. July...

Press release 2022/10/28

Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...

Press release 2022/09/12

Medivir to present at the H.C. Wainwright 24th Annual Global Investment Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/09/08

Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2022/09/01

News & Media

Medivir has completed a successful pre-IND meeting with the FDA

Medivir to present at the Erik Penser Bank Healthcare Day

Medivir recruits Pia Baumann as new Chief Medical Officer

Medivir to present at the Redeye Life Science Day

Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2022

Nomination Committee of Medivir appointed

Medivir to present at the H.C. Wainwright 24th Annual Global Investment Conference

Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting

Medivir to present at the Pareto Securities´ Healthcare conference

Medivir to present at the Erik Penser Bank Company Day

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2022

Jens Lindberg

Magnus Christensen